Problems at Nutex, Part Two: Misunderstood by Investors and Facing a Revenue Cliff As Schemes Unravel

Nutex looks like a profitable company with a solid balance sheet and rapid revenue growth, but under the surface it's actually a mediocre business propped up by alleged arbitration fraud, medical billing fraud, inflated receivables, and misleading accounting. The recent spike in revenue is temporary and is already reversing, while receivables are at risk of significant write-downs, and income is threatened by lawsuits and clawbacks.

NASDAQ: NUTX